Phase 3 trials are designed to...

• A. Test on the large group (1000-3000) to confirm effectiveness, monitor side effects, compare to other treatments, and determine safe use
• B. Determine dosage range in a small group
• C. Assess only safety in a small study
• D. Post-approval surveillance

Answer: (A)

Phase 3 trials aim to confirm that a drug works and is safe in a large, diverse group of patients, giving robust evidence that can support regulatory approval. By testing around a thousand or more participants, these studies compare the new therapy to standard treatments or placebo, detect less common side effects, and help establish practical usage guidelines such as who should use it, dosing, and monitoring. This larger, confirmatory evidence distinguishes Phase 3 from earlier stages that focus on safety and dosing in smaller groups, and from post‑approval monitoring that happens after a drug is approved.